Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

The primary objective of this phase 2, open-label, single-cohort, multicenter trial was to evaluate the efficacy of belumosudil 200 mg BID using the Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) after 24 weeks of therapy. The duration of the study was approximately 14 months (4 weeks for screening, 52 weeks of dosing period, and 4 weeks of Follow-up) Participants who had signed an Institutional Review Board/Independent Ethics Committee-(IRB/IEC)-approved informed consent form (ICF) and met all of the inclusion/exclusion criteria were enrolled. A total of 10 participants at 6 sites received belumosudil 200 mg in tablet form administered PO BID for 52 weeks. The total duration of the study is approximately 14 months: a 4-week screening period, a 52-week treatment period, and a 4-week follow-up. The primary endpoint was analyzed using Week 24 data. Efficacy was assessed throughout the 52-week dosing period using: * Composite Response Index in Systemic Sclerosis (CRISS) * Modified Rodnan Skin Score (mRSS) * Pulmonary Function Tests (PFTs) * Physician Global Assessment * Patient Global Assessment Safety was be assessed throughout the study and will include:. * Physical examinations (PEs) * Vital sign measurements * Weight measurements * Blood sample collection for hematology and chemistry; urinalysis * Electrocardiograms (ECGs) * Adverse event (AE) assessments * Concomitant medication assessments * Pregnancy testing for females of childbearing potential. Reasons for discontinuation of treatment because of adverse events were documented. Careful monitoring of all adverse events was carried out. Dosing could be reduced 1 dose level. If the dose was not tolerated, then the participant was discontinued from the study. If there is an interruption of dosing, after 14 days the participant was discontinued from the study. Participants were given a study drug diary to record the details of each dose of belumosudil 200 mg. Diaries were dispense/collected on each visit. Compliance with dosing was confirmed using participant diaries, which was examined at each visit by site staff to determine if dosing was as instructed per protocol and follow-up. A 4-Week Safety Follow-up Visit occurred 28 days (± 3 days) after the last dose of study drug.